Hemispherx Biopharma (HEB) Reports Q2 Loss of $0.01; Reports Implementation of Austerity Measures

Hemispherx Biopharma (NYSE: HEB) reported Q2 EPS of ($0.01), versus ($0.04) reported last year.

Hemispherx Biopharma has made changes to its senior management team and has implemented austerity measures which included the reduction of executive compensation and elimination of non-essential contractors and personnel. These measures have resulted in a significant reduction in costs and expenses. The company is now focusing on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the world.

For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.

You May Also Be Interested In

• Wendy's U.S. president to resign, company to create COO role
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c